(dtpa-phe(1))-octreotide and Kidney-Neoplasms

(dtpa-phe(1))-octreotide has been researched along with Kidney-Neoplasms* in 2 studies

Reviews

1 review(s) available for (dtpa-phe(1))-octreotide and Kidney-Neoplasms

ArticleYear
[Somatostatin analogs in the clinical management of pituitary neoplasms].
    Minerva endocrinologica, 2001, Volume: 26, Issue:3

    The medical approach to patients with secreting or clinically non-functioning pituitary adenoma as made considerable progress thanks to the use of new somatostatin analogs. They were first used to treat acromegaly in the mid 1980s and numerous studies have shown a reduction in GH concentration in over 90% of acromegalic patients. Good results were obtained using slow-release analog treatment also in TSH-secreting adenomas, whereas the therapeutic efficacy of these peptides in clinically non-functioning adenomas is still controversial. Treatment with somatostatin analogs improves symptoms, normalises hormone secretion and in some cases may induce a reduction in the volume of pituitary adenomas. Scintigraphy with octreotide may help to select patients who respond to this form of treatment.

    Topics: Acromegaly; Adenoma; Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Agents, Hormonal; Carcinoma; Humans; Indium Radioisotopes; Insulin-Like Growth Factor I; Kidney Neoplasms; Melanoma; Middle Aged; Octreotide; Pentetic Acid; Peptides, Cyclic; Pheochromocytoma; Pituitary Neoplasms; Predictive Value of Tests; Prolactinoma; Radionuclide Imaging; Radiopharmaceuticals; Sensitivity and Specificity; Somatostatin; Thymoma; Thymus Neoplasms; Thyroid Neoplasms; Thyrotropin; Treatment Outcome

2001

Other Studies

1 other study(ies) available for (dtpa-phe(1))-octreotide and Kidney-Neoplasms

ArticleYear
Imaging of renal cell cancer with radiolabelled octreotide.
    Nuclear medicine communications, 1993, Volume: 14, Issue:10

    Recently the presence of somatostatin receptors on human renal cell carcinomas has been demonstrated by autoradiographic techniques on surgically removed kidneys. In a prospective study we evaluated, by means of 111In-labelled octreotide scintigraphy, the in vivo tumour imaging in a group of patients with biopsy proven renal cell carcinomas at different tumour stages. Seven patients were studied. In three of them (43%) pathological tracer accumulation was demonstrated. In these patients 20 out of 23 known tumour localizations were clearly visualized. Tracer uptake could be inhibited by prior administration of cold octreotide. We conclude that 111In-octreotide scintigraphy can be used to demonstrate, in vivo, metastatic renal cell carcinoma.

    Topics: Aged; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Octreotide; Pentetic Acid; Prospective Studies; Radionuclide Imaging

1993